Paper Details

  1. Home
  2. Paper Details

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

Author: AbetzLinda, AbishSharon, AgaogluLeyla, BaladiJean-Francois, BejaouiMohamed, CappelliniMaria Domenica, CarioHolger, CoatesThomas, FersterAlina, GirotRobert, JengMichael, LaiMaria Eliana, LoggettoSandra, MangiagliAntonio, OpitzHerbert, PorterJohn, Ressayre-DjafferCatherine, RofailDiana, StraussGabriele, VichinskyElliott, WatmanNora, ZoumbosNicolaos

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Deferasirox, an orally administered iron chelator, is an alternative to deferoxamine (DFO) for treating iron overload in patients with transfusion-dependent disorders.
Paper Details　
Original Abstract of the Article :
Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treatment of iron overload in patients with transfusion-dependent disorders such as beta-thalassemia, requires regular subcutaneous or intravenous infusions. This can lead to reduced quality of life and poor adherence...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2007.05.007

データ提供：米国国立医学図書館（NLM）

Deferasirox: A New Hope for Iron Overload in Beta-Thalassemia

This study delves into the vast and often challenging terrain of [iron overload] in patients with [beta-thalassemia], exploring the potential of [deferasirox], an oral iron chelator, as a new treatment option. The researchers compared [deferasirox] with [deferoxamine], the current standard of care, which requires regular injections, to assess its effectiveness and impact on patient-reported outcomes.

Improving Patient Outcomes in Beta-Thalassemia

The study found that [deferasirox], due to its oral administration, has the potential to improve [quality of life] and [adherence] to treatment in patients with [beta-thalassemia]. The researchers suggest that [deferasirox] could lead to reduced morbidity and mortality in these patients.

Navigating the Challenges of Iron Overload

This research highlights the importance of finding effective and convenient treatment options for [iron overload] in patients with [beta-thalassemia]. The study's findings suggest that [deferasirox] could offer a significant improvement over the current standard of care.

Dr.Camel's Conclusion

This study offers a glimpse of hope for patients with beta-thalassemia who struggle with iron overload. Deferasirox, an oral iron chelator, appears to be a promising alternative to deferoxamine, potentially improving quality of life and treatment adherence. However, further research is needed to fully evaluate the long-term benefits and risks of deferasirox.

Date :
  1. Date Completed 2007-09-05
  2. Date Revised 2022-11-18
Further Info :

Pubmed ID

17697909

DOI: Digital Object Identifier

10.1016/j.clinthera.2007.05.007

Related Literature

Article Analysis
・Effective treatment of iron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.